THROMBOTIC THROMBOCYTOPENIC PURPURA - EVIDENCE THAT INFUSION RATHER THAN REMOVAL OF PLASMA INDUCES REMISSION OF THE DISEASE

被引:60
作者
RUGGENENTI, P
GALBUSERA, M
CORNEJO, RP
BELLAVITA, P
REMUZZI, G
机构
[1] OSPED RIUNITI BERGAMO,DIV NEPHROL,I-24100 BERGAMO,ITALY
[2] OSPED RIUNITI BERGAMO,IMMUNOHEMATOL SECT,I-24100 BERGAMO,ITALY
关键词
THROMBOTIC THROMBOCYTOPENIC PURPURA; PLASMA INFUSION; PLASMA EXCHANGE; PLASMA REMOVAL; VONWILLEBRAND FACTOR;
D O I
10.1016/S0272-6386(12)80752-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Plasma exchange has recently been reported to be more effective than plasma infusion for the treatment of thrombotic thrombocytopenic purpura (TTP). However, in the only available controlled study, the plasma infused during the exchange procedure was three times that given by infusion alone. Here we report the case of a patient with chronic relapsing TTP who had 21 relapsing episodes in the last 3 years. During 18 relapses, infusion of plasma, as infusion alone or in the context of an exchange procedure, invariably induced remission of the disease. By contrast, plasma removal alone (replaced with albumin and saline) was ineffective in three further consecutive relapses so that infusion was eventually necessary to induce remission. We concluded that the effective component of plasma exchange in TTP is infusion, rather than removal of plasma. Unusually large von Willebrand factor (ULvWF) multimers were found during both acute and remission phases, possibly reflecting intravascular leakage from ongoing endothelial cell injury. A relative increase of the 176-kd fragment and a relative decrease of the 225-kd subunit were demonstrated during the acute phase, indicating in vivo proteolytic vWF fragmentation. Since in vitro evidence is available that such fragments of vWF induce platelet aggregation, it is speculated that protease inhibitors of normal plasma help restore normal vWF processing activity in the circulation, which explains remission of the disease associated with the plasma infusion. © 1993, National Kidney Foundation, Inc.. All rights reserved.
引用
收藏
页码:314 / 318
页数:5
相关论文
共 24 条
[11]  
MURPHY WG, 1987, BLOOD, V70, P1683
[12]  
REMUZZI G, 1987, THROMB DIATH HAEMO, P673
[13]  
ROCK GA, 1991, NEW ENGL J MED, V325, P391
[14]  
ROWE JM, 1985, AM J HEMATOL, V20, P161
[15]  
RUGGENENTI P, 1991, NEW ENGL J MED, V324, P1065
[16]  
RUGGERI ZM, 1981, BLOOD, V57, P1140
[17]  
RUGGERI ZM, 1982, BLOOD, V59, P1272
[18]   PLATELETS HAVE MORE THAN ONE BINDING-SITE FOR VONWILLEBRAND-FACTOR [J].
RUGGERI, ZM ;
DEMARCO, L ;
GATTI, L ;
BADER, R ;
MONTGOMERY, RR .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 72 (01) :1-12
[19]  
SAKARIASSEN KS, 1984, BLOOD, V63, P996
[20]   HIGH-MOLECULAR-WEIGHT KININOGEN IS AN INHIBITOR OF PLATELET CALPAIN [J].
SCHMAIER, AH ;
BRADFORD, H ;
SILVER, LD ;
FARBER, A ;
SCOTT, CF ;
SCHUTSKY, D ;
COLMAN, RW .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (05) :1565-1573